Becton, Dickinson and Company: financial statements

BDXNYSEHealthcare · Surgical & Medical Instruments & Apparatus

Price

$217.75

November 16, 2026Market cap $62.1B

What Ploutos Investor adds for Becton, Dickinson and Company

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 23% since Aug 6, 2026, when the 10-Q these figures come from was filed ($177.07 then, $218.03 on Nov 13, 2026). The figures date from before that move.10-Q
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2023–FY2025 fiscal years

Click a line to see it on the chart.

Revenue

+6.2% a year over 2 years

LineFY2023FY2024FY2025Average a year
Revenue $19.4B$20.2B$21.8B+6.2%
Cost of revenue $11.2B$11.1B$11.9B+3.1%
Gross profit $8.2B$9.1B$9.9B+10.2%
Operating income $2.1B$2.4B$2.6B+10.5%
Net income $1.5B$1.7B$1.7B+6.3%
Earnings per share $4.94$5.86$5.82+8.5%
Earnings per share, basic $4.97$5.88$5.83+8.3%
Margins
Gross margin 42.2%45.2%45.4%
Operating margin 10.9%11.9%11.8%
Net margin 7.7%8.4%7.7%

Financial statements

BDX's revenue, profits and cash flows from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2023: Medical $9.5B, Interventional $4.7B, Life Sciences $5.1B
  • FY2024: Medical $10.1B, Interventional $5.0B, Life Sciences $5.2B
  • FY2025: Medical $11.5B, Interventional $5.2B, Life Sciences $5.2B
SegmentFY2023FY2024FY2025Share FY2025
Medical$9.5B$10.1B$11.5B52%
Interventional$4.7B$5.0B$5.2B24%
Life Sciences$5.1B$5.2B$5.2B24%

By segment

BDX's revenue by segment from FY2011 to FY2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 18 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$5.4B Due within 2 years$839M Leases87% Pensions funded

When the debt falls due

Sep 30, 2025

Due within 2 years

$5.4B

Principal of loans and bonds falling due, from the annual report dated September 30, 2025, without leases and interest. The filing

  • 9/2026: $2.2B
  • 9/2027: $3.2B

Leases

Sep 30, 2025

Operating leases

$839M

Finance leases

–

The liability is the present value of the rent still to pay, at September 30, 2025. It is not counted in the ladder's debt. The filing

Pension plans

Sep 30, 2025

Defined-benefit pensions

87%funded

Deficit $371M.

The obligation is the present value of the pensions employees have already earned, at September 30, 2025. A deficit is the company's to fill with contributions. The filing

ObligationPlan assets

Goodwill by segment

Sep 30, 2025

Total goodwill

$26.6B

  • Medical$12.9B49%

Goodwill is what the company paid in acquisitions above the value of what it bought, at September 30, 2025. If an acquisition earns less, the goodwill is impaired and earnings fall. The filing

$26.6BTotal goodwill

From the statutory to the effective tax rate, FY2025

Sep 30, 2025

Statutory rate

21.0%

Effective rate

10.8%

-10.2 pts

The company paid 10.8% in tax on its profit, 10.2 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Foreign rate differential

-14.0 pts

Difference the filing does not itemize

+3.8 pts

Effective rate

10.8%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$324M ahead of the shares0.5% of market value

Besides its $16.8B of debt, $324M of other claims rank ahead of the shares, about 0.5% of the market value.

Ahead of the shares

at Sep 30, 2025; $371M before tax, after tax at 13%
$324M

From the balance sheet of June 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 16, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Where the change in earnings per share came from

Diluted earnings per share went from $5.86 in the fiscal year to Sep 30, 2024 to $5.82 in the year to Sep 30, 2025, a change of -$0.04.

Measured by size, 66.3% of the movement came from outside sales and operating margin: interest and other items, the tax rate, what went to others and the share count.

+$0.59
-$0.04
-$0.92
+$0.28
+$0.05

Earnings per share is split as sales times operating margin, plus interest and other items, after tax, times the part that goes to the common shareholders, divided by the diluted share count. Each source's part is its average effect over every order in which the six can change, so the parts add up exactly to the change. From the annual reports; net income over the diluted count matches the earnings per share the company filed within 2%.

Receivables and inventory against sales

In the quarter to Jun 30, 2026, sales were +5.4% on the same quarter a year earlier, and receivables -19.7%. Inventory was -16.0%, against +7.1% for the cost of sales.

a year earlier 56 days
43 days
a year earlier 143 days
112 days

Balances at Jun 30, 2026 and Jun 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Taxes: deferred and paid

The deferred part was -233.5% of the tax charge in the year to Sep 30, 2025. The rows show the last 3 years.

Cash taxes paid were 88.5% of the current tax charge in the year to Sep 30, 2025.

Deferred share, year to Sep 30, 2025-$474M of $203M
-233.5%
Deferred share, year to Sep 30, 2024-$211M of $300M
-70.3%
Deferred share, year to Sep 30, 2023-$622M of $132M
-471.2%
$599M paid, $677M current
88.5%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Becton, Dickinson and Company's filings show?

These are Becton, Dickinson and Company's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BDX's financials

Didn't find what you were looking for?

Ask us
How much revenue did BDX have in FY2025?

Becton, Dickinson and Company had revenue of $21.8B and net income of $1.7B in fiscal FY2025, a net margin of 7.7%.

How much debt does BDX have?

On September 30, 2025 Becton, Dickinson and Company had total assets of $55.3B, debt of $19.2B and shareholders' equity of $25.4B.

How much free cash flow does BDX have?

In fiscal FY2025 Becton, Dickinson and Company had cash from operations of $3.4B and spent $760M on capital expenditure, leaving $2.7B of free cash flow.

Where are the figures from?

From Becton, Dickinson and Company's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.